Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

Inclusion Criteria: * Male or female subject's ≥ 18 years of age, able to give informed consent to the study. * Fibromyalgia diagnosis based on The 2011 modification of the American College of Rheumatology (ACR) 's 2010 preliminary criteria for diagnosing fibromyalgia (2011ModCr) * A baseline score ≥ 60 on the FIQR * Subject's current medications to treat fibromyalgia, including pain medicines, anti-depressants, sleep medications must be on a stable dose for at least 30 days. * Subject's current narcotic medication must be on a stable dose for at least 30 days prior to randomization * Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control: have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility. Exclusion Criteria: * Parenteral iron use within 4 weeks prior to screening. * History of \> 10 blood transfusions in the past 2 years. * Anticipated need for blood transfusion during the study. * Known hypersensitivity reaction to any component of Injectafer® (Ferric Carboxymaltose). * Current or acute or chronic infection other than viral upper respiratory tract infection * Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for ≥ 5 years). *…